According to a recent LinkedIn post from Click Therapeutics Inc, the company is emphasizing the strategic role of Prescription Drug Use-Related Software (PDURS) as a tool to enhance pharmaceutical brands beyond traditional drug products. The post, referencing a collaborative piece with IQVIA, frames PDURS as a way to link digital innovation with commercial outcomes in the life sciences sector.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights industry headwinds, noting that U.S. drug approvals have remained near 50 per year and that patent expirations could drive an estimated $300 billion in revenue losses by 2030. It also notes increasing payer pressure for greater clinical and economic value from existing therapies, positioning software-driven clinical benefits as one potential response.
According to the post, software can now be integrated into FDA-authorized package inserts as part of a “Software-Enhanced Drug™” model, enabling pharma companies to augment patient care, differentiate on efficacy and defend market share beyond loss of exclusivity through SaMD-based intellectual property. The message suggests this approach could help extend product lifecycles and mitigate revenue erosion for established franchises.
The company’s LinkedIn post also underscores Click Therapeutics’ focus on developing software-as-a-medical-device and digital therapeutics designed for adjunctive use with standard pharmacotherapy. For investors, this emphasis on PDURS and Software-Enhanced Drugs™ may indicate that Click is positioning itself as an enabling partner for pharma seeking to protect and grow branded revenues, potentially expanding its addressable market in digital health and pharma innovation services.